In the case of Oxford and Astra Zeneca the answer is quite probably not. For instance, the university team will almost certainly have received a huge amount of money from governments, such as the €56 million Oxford received from the European Research Council in December 2019.
Oxford University has won the largest amount of new research funding in the UK from the European Research Council (ERC).
www.ox.ac.uk
Similarly, both the UK government and the EU gave Astra Zeneca huge sums to develop their manufacturing capabilities to produce the vaccine, with most of the orders for those vaccines given well in advance of them actually being approved for use. Most of the expense of drugs in ordinary times is due to the significant risk involved in developing them. This process was about as de-risked as it was possible to get, so I hardly think we can start knighting AZ for their charity.
The notion of providing it at cost doesn't make much sense either as the UK government is paying significantly more for the vaccine than the EU is. Given that they're both coming from the same facilities (or should be), are they making a loss on some vaccines or a profit on some? As the article below about branding illustrates, the world won't be looking on Pfizer as profiteering from this but as the company that has delivered on its promises. The same can't be said for AZ who have had a shocker (and that's got bugger all to do with apparently "hating Britain").
After almost two centuries of successful innovation, one company is about to get a huge fillip from the rollout of its vaccine.
www.marketingweek.com